Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rationally engineered therapeutic proteins with reduced immunogenicity.

Shabnam Tangri1, Bianca R Mothé, Julie Eisenbraun

  • 1Epimmune, San Diego, CA 92121, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|March 8, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA tapasin independence: broader peptide repertoire and HIV control.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4<sup>+</sup> T Cells in COVID-19.

Cell·2020
Same author

Comparison of HLA ligand elution data and binding predictions reveals varying prediction performance for the multiple motifs recognized by HLA-DQ2.5.

Immunology·2020
Same author

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.

Cell·2020
Same author

Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

Cross-reactive memory T cells and herd immunity to SARS-CoV-2.

Nature reviews. Immunology·2020

Reducing specific protein regions in erythropoietin (Epo) can lower immune responses. This study demonstrates a systematic method to decrease the immunogenicity of protein therapeutics by modifying helper T lymphocyte (HTL) epitopes.

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • Chronic administration of protein therapeutics can trigger adverse immune responses.
  • Protein immunogenicity is often linked to specific helper T lymphocyte (HTL) epitopes.
  • Erythropoietin (Epo) is a protein therapeutic where immunogenicity is a concern.

Purpose of the Study:

  • To test the hypothesis that modifying immunodominant HTL epitopes can reduce protein drug immunogenicity.
  • To engineer Epo analogs with reduced immunogenicity.
  • To demonstrate a systematic approach for developing less immunogenic protein therapeutics.

Main Methods:

  • Identified HTL epitopes within Epo (regions 91-120 and 126-155).
  • Engineered analog epitopes with reduced major histocompatibility complex (MHC) binding affinity.

Related Experiment Videos

  • Assessed in vitro immunogenicity of modified epitopes and Epo analogs.
  • Evaluated bioactivity and non-immunogenicity of modified Epo in vitro.

    • Main Results:

    • Two key regions in Epo contained HTL epitopes recognized across diverse HLA-DR types.
    • Engineered analog epitopes showed reduced in vitro immunogenicity.
    • Modified Epo forms were bioactive and non-immunogenic in vitro.

    Conclusions:

    • Immunogenicity of protein drugs can be systematically reduced by targeting HTL epitopes.
    • Modifying MHC binding affinity of HTL epitopes is a viable strategy to lower protein immunogenicity.
    • This approach offers a predictable method for developing safer protein therapeutics like Epo.